BLAKE DOERR: Open Payments
NPI 1588345110 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$972 in 43 payments from 20 companies in 2025. Trend: 2023 $790 · 2024 $2,487 · 2025 $972
Food & beverage: $972
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 6 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $86 |
| AstraZeneca Pharmaceuticals LP | 4 | $81 |
| Sumitomo Pharma America, Inc. | 4 | $74 |
| GlaxoSmithKline, LLC. | 4 | $64 |
| Janssen Biotech, Inc. | 2 | $60 |
| Lilly USA, LLC | 2 | $58 |
| Ferring Pharmaceuticals Inc. | 2 | $51 |
| BioCryst US Sales Co., LLC | 2 | $50 |
| IMMUNITYBIO, INC. | 2 | $44 |
Products named: DUPIXENT, GEMTESA, ERLEADA, AIRSUPRA, EBGLYSS, CUVITRU, Xolair, ADSTILADRIN.
Industry payments across FL — which companies pay providers there.
